During this study, an analytical protocol for measuring hepatic de novo lipogenesis (DNL) using deuterium oxide (²H₂O) will be implemented and validated in healthy participants.
Inclusion Criteria:
Exclusion Criteria:
Participants will be excluded from the study based on self-reported health status if they meet any of the following conditions:
All participants will undergo a 10-day oral stable isotope labelling period with deuterium oxide (²H₂O). Blood samples will be collected at baseline, on Day 11, and at washout Weeks 4, 6, and 8. Deuterium (²H) enrichment in plasma water and VLDL-TG palmitate will be measured to determine fractional hepatic de novo lipogenesis and characterize the washout of ²H₂O.
Leuven, Vlaams-Brabant 3000, Belgium
Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis
Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans
De Novo Lipogenesis in Severity of NAFLD
De Novo Lipogenesis and Insulin Sensitivity in Obese
A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
Establishment of the 2H-labeling Protocol at Pennington Biomedical Research Center
Alcohol Induced de Novo Lipogenesis in Women